Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 101

Similar articles for PubMed (Select 24066937)

1.

Vildagliptin restores renal myogenic function and attenuates renal sclerosis independently of effects on blood glucose or proteinuria in zucker diabetic fatty rat.

Vavrinec P, Henning RH, Landheer SW, Wang Y, Deelman LE, Dokkum RP, Buikema H.

Curr Vasc Pharmacol. 2014;12(6):836-44.

PMID:
24066937
2.

Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats.

Liu WJ, Xie SH, Liu YN, Kim W, Jin HY, Park SK, Shao YM, Park TS.

J Pharmacol Exp Ther. 2012 Feb;340(2):248-55. doi: 10.1124/jpet.111.186866. Epub 2011 Oct 24.

3.

Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes.

Kodera R, Shikata K, Takatsuka T, Oda K, Miyamoto S, Kajitani N, Hirota D, Ono T, Usui HK, Makino H.

Biochem Biophys Res Commun. 2014 Jan 17;443(3):828-33. doi: 10.1016/j.bbrc.2013.12.049. Epub 2013 Dec 14.

PMID:
24342619
4.

Attenuation of renovascular damage in Zucker diabetic fatty rat by NWT-03, an egg protein hydrolysate with ACE- and DPP4-inhibitory Activity.

Wang Y, Landheer S, van Gilst WH, van Amerongen A, Hammes HP, Henning RH, Deelman LE, Buikema H.

PLoS One. 2012;7(10):e46781. doi: 10.1371/journal.pone.0046781. Epub 2012 Oct 10.

5.

Vildagliptin in clinical practice: a review of literature.

Banerjee M, Younis N, Soran H.

Expert Opin Pharmacother. 2009 Nov;10(16):2745-57. doi: 10.1517/14656560903302265. Review.

PMID:
19874253
6.

Effects of long-term treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin on islet endocrine cells in non-obese type 2 diabetic Goto-Kakizaki rats.

Inaba W, Mizukami H, Kamata K, Takahashi K, Tsuboi K, Yagihashi S.

Eur J Pharmacol. 2012 Sep 15;691(1-3):297-306. doi: 10.1016/j.ejphar.2012.07.030. Epub 2012 Jul 20.

PMID:
22820107
7.

Effects of combination therapy with vildagliptin and valsartan in a mouse model of type 2 diabetes.

Miyagawa K, Kondo T, Goto R, Matsuyama R, Ono K, Kitano S, Kawasaki S, Igata M, Kawashima J, Matsumura T, Motoshima H, Araki E.

Cardiovasc Diabetol. 2013 Nov 4;12:160. doi: 10.1186/1475-2840-12-160.

8.

Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced glycation end product-receptor axis.

Matsui T, Nishino Y, Takeuchi M, Yamagishi S.

Pharmacol Res. 2011 May;63(5):383-8. doi: 10.1016/j.phrs.2011.02.003. Epub 2011 Feb 12.

PMID:
21320599
9.
10.

Angiotensin-(1-7) attenuates diabetic nephropathy in Zucker diabetic fatty rats.

Giani JF, Burghi V, Veiras LC, Tomat A, Muñoz MC, Cao G, Turyn D, Toblli JE, Dominici FP.

Am J Physiol Renal Physiol. 2012 Jun 15;302(12):F1606-15. doi: 10.1152/ajprenal.00063.2012. Epub 2012 Apr 4.

11.

Dual therapy of vildagliptin and telmisartan on diabetic nephropathy in experimentally induced type 2 diabetes mellitus rats.

Sharma AK, Kanawat DS, Mishra A, Dhakad PK, Sharma P, Srivastava V, Joshi S, Joshi M, Raikwar SK, Kurmi MK, Srinivasan BP.

J Renin Angiotensin Aldosterone Syst. 2014 Dec;15(4):410-8. doi: 10.1177/1470320313475908. Epub 2013 Feb 8.

PMID:
23396552
12.

Chronic DPP-IV inhibition with PKF-275-055 attenuates inflammation and improves gene expressions responsible for insulin secretion in streptozotocin induced diabetic rats.

Akarte AS, Srinivasan BP, Gandhi S, Sole S.

Eur J Pharm Sci. 2012 Sep 29;47(2):456-63. doi: 10.1016/j.ejps.2012.07.003. Epub 2012 Jul 16.

PMID:
22800967
13.

Vildagliptin ameliorates oxidative stress and pancreatic beta cell destruction in type 1 diabetic rats.

Ávila Dde L, Araújo GR, Silva M, Miranda PH, Diniz MF, Pedrosa ML, Silva ME, de Lima WG, Costa DC.

Arch Med Res. 2013 Apr;44(3):194-202. doi: 10.1016/j.arcmed.2013.03.004. Epub 2013 Mar 21.

PMID:
23523961
14.

A randomized, placebo-controlled, double-blind, prospective trial to evaluate the effect of vildagliptin in new-onset diabetes mellitus after kidney transplantation.

Haidinger M, Werzowa J, Voigt HC, Pleiner J, Stemer G, Hecking M, Döller D, Hörl WH, Weichhart T, Säemann MD.

Trials. 2010 Oct 6;11:91. doi: 10.1186/1745-6215-11-91.

15.

Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition.

Rizzo MR, Barbieri M, Marfella R, Paolisso G.

Diabetes Care. 2012 Oct;35(10):2076-82. Epub 2012 Jun 11. Erratum in: Diabetes Care. 2014 Feb;37(2):587.

16.

Beneficial effects of vildagliptin on retinal injury in obese type 2 diabetic rats.

Maeda S, Yamagishi S, Matsui T, Nakashima S, Ojima A, Maeda S, Nishino Y, Ishibashi Y, Yoshida Y, Yamakawa R.

Ophthalmic Res. 2013;50(4):221-6. doi: 10.1159/000354116. Epub 2013 Sep 25.

PMID:
24081217
17.

Effects of vildagliptin versus sitagliptin, on cardiac function, heart rate variability and mitochondrial function in obese insulin-resistant rats.

Apaijai N, Pintana H, Chattipakorn SC, Chattipakorn N.

Br J Pharmacol. 2013 Jul;169(5):1048-57. doi: 10.1111/bph.12176.

18.

Efficacy of vildagliptin in combination with insulin in patients with type 2 diabetes and severe renal impairment.

Lukashevich V, Schweizer A, Foley JE, Dickinson S, Groop PH, Kothny W.

Vasc Health Risk Manag. 2013;9:21-8. doi: 10.2147/VHRM.S39300. Epub 2013 Jan 23.

19.

Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes.

D'Alessio DA, Denney AM, Hermiller LM, Prigeon RL, Martin JM, Tharp WG, Saylan ML, He Y, Dunning BE, Foley JE, Pratley RE.

J Clin Endocrinol Metab. 2009 Jan;94(1):81-8. doi: 10.1210/jc.2008-1135. Epub 2008 Oct 28.

20.

The dipeptidyl peptidase-4 (DPP-4) inhibitor vildagliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis.

Ito M, Abe M, Okada K, Sasaki H, Maruyama N, Tsuchida M, Higuchi T, Kikuchi F, Soma M.

Endocr J. 2011;58(11):979-87. Epub 2011 Sep 15.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk